drugset
drugset / Trial / NCT05098262

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State

NCT05098262 ↗

Phase 1 Completed 40 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy subjects at Fasting State

Timeline

Start
2021-10-31
Primary completion
2022-01-03
Completion
2022-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-5210 Unknown — —
Subject DA-5210-R Unknown — —

Indications

No indication recorded.